BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Davis MP. Twelve Reasons for Considering Buprenorphine as a Frontline Analgesic in the Management of Pain. The Journal of Supportive Oncology 2012;10:209-19. [DOI: 10.1016/j.suponc.2012.05.002] [Cited by in Crossref: 105] [Cited by in F6Publishing: 90] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Webster L, Gruener D, Kirby T, Xiang Q, Tzanis E, Finn A. Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine. Pain Med 2016;17:899-907. [PMID: 26917621 DOI: 10.1093/pm/pnv110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
2 Herring AA, Perrone J, Nelson LS. Managing Opioid Withdrawal in the Emergency Department With Buprenorphine. Annals of Emergency Medicine 2019;73:481-7. [DOI: 10.1016/j.annemergmed.2018.11.032] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 14.3] [Reference Citation Analysis]
3 Salili AR, Müller D, Skendaj R, Jehle AW, Taegtmeyer AB. Breakthrough Pain Associated with a Reduction in Serum Buprenorphine Concentration during Dialysis. Clinical Therapeutics 2016;38:212-5. [DOI: 10.1016/j.clinthera.2015.10.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
4 Thompson J. Treating cancer pain: the palliative nursing dilemma. Int J Palliat Nurs 2016;22:12. [PMID: 26804951 DOI: 10.12968/ijpn.2016.22.1.12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Lim SCB, Schug S, Krishnarajah J. The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. Pain Med 2019;20:143-52. [PMID: 29309700 DOI: 10.1093/pm/pnx321] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pergolizzi JV, Gharibo C, Ho K. Treatment Considerations for Cancer Pain: A Global Perspective. Pain Pract 2015;15:778-92. [DOI: 10.1111/papr.12253] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
7 Pergolizzi JV Jr, Raffa RB, Fleischer C, Zampogna G, Taylor R Jr. Management of moderate to severe chronic low back pain with buprenorphine buccal film using novel bioerodible mucoadhesive technology. J Pain Res 2016;9:909-16. [PMID: 27826213 DOI: 10.2147/JPR.S87952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
8 Prommer E. Buprenorphine for Cancer Pain: Is It Ready for Prime Time? Am J Hosp Palliat Care 2015;32:881-9. [DOI: 10.1177/1049909114547227] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Gimbel J, Spierings ELH, Katz N, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study. Pain 2016;157:2517-26. [PMID: 27434505 DOI: 10.1097/j.pain.0000000000000670] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
10 Browne CA, Jacobson ML, Lucki I. Novel Targets to Treat Depression: Opioid-Based Therapeutics. Harv Rev Psychiatry 2020;28:40-59. [DOI: 10.1097/hrp.0000000000000242] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 5.5] [Reference Citation Analysis]
11 Bai SA, Xiang Q, Finn A. Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. Clinical Therapeutics 2016;38:358-69. [DOI: 10.1016/j.clinthera.2015.12.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
12 Marino R, Perrone J, Nelson LS, Wiegand TJ, Schwarz ES, Wax PM, Stolbach AI. ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder. J Med Toxicol 2019;15:307-9. [PMID: 31414402 DOI: 10.1007/s13181-019-00728-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Khanna IK, Pillarisetti S. Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res 2015;8:859-70. [PMID: 26672499 DOI: 10.2147/JPR.S85951] [Cited by in Crossref: 13] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
14 Markman JD, Barbosa WA, Gewandter JS, Frazer M, Rast S, Dugan M, Nandigam K, Villareal A, Kwong TC. Interpretation of Urine Drug Testing Results in Patients Using Transdermal Buprenorphine Preparations for the Treatment of Chronic Noncancer Pain: Table 1. Pain Med 2015;16:1132-6. [DOI: 10.1111/pme.12740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Mercadante S. Opioid metabolism and clinical aspects. European Journal of Pharmacology 2015;769:71-8. [DOI: 10.1016/j.ejphar.2015.10.049] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
16 Demarest SP, Gill RS, Adler RA. Opioid Endocrinopathy. Endocrine Practice 2015;21:190-9. [DOI: 10.4158/ep14339.ra] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 3.1] [Reference Citation Analysis]
17 Mariottini C, Gergov M, Ojanperä I. Determination of buprenorphine, norbuprenorphine, naloxone, and their glucuronides in urine by liquid chromatography-tandem mass spectrometry. Drug Test Anal 2021. [PMID: 34047070 DOI: 10.1002/dta.3104] [Reference Citation Analysis]
18 Pergolizzi JV, Lequang JA, Taylor R, Ossipov MH, Colucci D, Raffa RB. Designing safer analgesics: a focus on μ-opioid receptor pathways. Expert Opinion on Drug Discovery 2018;13:965-72. [DOI: 10.1080/17460441.2018.1511539] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
19 Manandhar P, Connor M, Santiago M. Tapentadol shows lower intrinsic efficacy at µ receptor than morphine and oxycodone. Pharmacol Res Perspect 2022;10:e00921. [PMID: 35084120 DOI: 10.1002/prp2.921] [Reference Citation Analysis]
20 Chen YH, Wu KL, Tsai MT, Chien WH, Chen ML, Wang Y. Methadone enhances human influenza A virus replication. Addict Biol 2017;22:257-71. [PMID: 26350582 DOI: 10.1111/adb.12305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
21 Mendoza S, Rivera AS, Hansen HB. Re-racialization of Addiction and the Redistribution of Blame in the White Opioid Epidemic: Re-racialized Addiction and Redistributed Blame. Medical Anthropology Quarterly 2019;33:242-62. [DOI: 10.1111/maq.12449] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
22 Powell VD, Rosenberg JM, Yaganti A, Garpestad C, Lagisetty P, Shannon C, Silveira MJ. Evaluation of Buprenorphine Rotation in Patients Receiving Long-term Opioids for Chronic Pain: A Systematic Review. JAMA Netw Open 2021;4:e2124152. [PMID: 34495339 DOI: 10.1001/jamanetworkopen.2021.24152] [Reference Citation Analysis]
23 Pasternak GW, Pan YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev 2013;65:1257-317. [PMID: 24076545 DOI: 10.1124/pr.112.007138] [Cited by in Crossref: 293] [Cited by in F6Publishing: 265] [Article Influence: 32.6] [Reference Citation Analysis]
24 Wang Y, Cipriano A, Munera C, Harris SC. Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects: Transdermal Administration of Buprenorphine. The Journal of Clinical Pharmacology 2016;56:1263-71. [DOI: 10.1002/jcph.718] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
25 Dalal S, Chitneni A, Berger AA, Orhurhu V, Dar B, Kramer B, Nguyen A, Pruit J, Halsted C, Kaye AD, Hasoon J. Buprenorphine for Chronic Pain: A Safer Alternative to Traditional Opioids. Health Psychol Res 2021;9:27241. [PMID: 34746493 DOI: 10.52965/001c.27241] [Reference Citation Analysis]
26 Kosel J, Bobik P, Tomczyk M. Buprenorphine – the unique opioid adjuvant in regional anesthesia. Expert Review of Clinical Pharmacology 2015;9:375-83. [DOI: 10.1586/17512433.2016.1141047] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
27 Cote J, Montgomery L. Sublingual buprenorphine as an analgesic in chronic pain: a systematic review. Pain Med 2014;15:1171-8. [PMID: 24995716 DOI: 10.1111/pme.12386] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
28 Ding H, Czoty PW, Kiguchi N, Cami-Kobeci G, Sukhtankar DD, Nader MA, Husbands SM, Ko MC. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Proc Natl Acad Sci U S A 2016;113:E5511-8. [PMID: 27573832 DOI: 10.1073/pnas.1605295113] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 10.8] [Reference Citation Analysis]
29 Lo Bianco G, Papa A, Schatman ME, Tinnirello A, Terranova G, Leoni MLG, Shapiro H, Mercadante S. Practical Advices for Treating Chronic Pain in the Time of COVID-19: A Narrative Review Focusing on Interventional Techniques. J Clin Med 2021;10:2303. [PMID: 34070601 DOI: 10.3390/jcm10112303] [Reference Citation Analysis]
30 Wolfe RC. Perioperative Buprenorphine. J Perianesth Nurs 2019;34:867-70. [PMID: 31204269 DOI: 10.1016/j.jopan.2019.05.001] [Reference Citation Analysis]
31 Covington EC, Argoff CE, Ballantyne JC, Cowan P, Gazelka HM, Hooten WM, Kertesz SG, Manhapra A, Murphy JL, Stanos SP Jr, Sullivan MD. Ensuring Patient Protections When Tapering Opioids: Consensus Panel Recommendations. Mayo Clin Proc 2020;95:2155-71. [PMID: 33012347 DOI: 10.1016/j.mayocp.2020.04.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
32 Butler S. Buprenorphine—Clinically useful but often misunderstood. Scandinavian Journal of Pain 2013;4:148-52. [DOI: 10.1016/j.sjpain.2013.05.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
33 Schug SA, Chandrasena C. Pain management of the cancer patient. Expert Opin Pharmacother 2015;16:5-15. [PMID: 25479712 DOI: 10.1517/14656566.2015.980723] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
34 Penno J, Young J, Ding J, Moushi J, Chou J. Sublingual buprenorphine for acute postoperative cancer pain: a retrospective study. J Pharm Pract Res 2021;51:390-5. [DOI: 10.1002/jppr.1748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Machado FC, Neto GC, Paiva LO, Soares TC, Nakamura RK, Nascimento LF, Campana CS, Lustosa LAMM, Cortez RA, Ashmawi HA. [Transdermal buprenorphine for acute postoperative pain: a systematic review]. Braz J Anesthesiol 2020;70:419-28. [PMID: 32819729 DOI: 10.1016/j.bjan.2020.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Londhe S, Patwardhan M, Shah R, Oak M. Efficacy and Safety of Buprenorphine Transdermal Patch for Immediate Postoperative Analgesia After Total Knee Arthroplasty Surgery. J Arthroplasty 2020;35:S178-81. [PMID: 32201109 DOI: 10.1016/j.arth.2020.02.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
37 Aiyer R, Gulati A, Gungor S, Bhatia A, Mehta N. Treatment of Chronic Pain With Various Buprenorphine Formulations: A Systematic Review of Clinical Studies. Anesthesia & Analgesia 2018;127:529-38. [DOI: 10.1213/ane.0000000000002718] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 6.3] [Reference Citation Analysis]
38 Mendoza S, Rivera-Cabrero AS, Hansen H. Shifting blame: Buprenorphine prescribers, addiction treatment, and prescription monitoring in middle-class America. Transcult Psychiatry 2016;53:465-87. [PMID: 27488225 DOI: 10.1177/1363461516660884] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
39 Kaski S, Marshalek P, Herschler J, Wen S, Zheng W. Sublingual Buprenorphine/Naloxone and Multi-Modal Management for High-Risk Chronic Pain Patients. J Clin Med 2021;10:973. [PMID: 33801173 DOI: 10.3390/jcm10050973] [Reference Citation Analysis]
40 Seecof OM, Kuwata C, DiBiase J, Popp B. Exploring the Barriers to Buprenorphine Therapy for Cancer-Related Pain and Concurrent Opioid Use Disorder: A Case Report. J Palliat Med 2022. [PMID: 35861726 DOI: 10.1089/jpm.2022.0182] [Reference Citation Analysis]
41 Vijayaraghavan R. Autoinjector device for rapid administration of drugs and antidotes in emergency situations and in mass casualty management. J Int Med Res 2020;48:300060520926019. [PMID: 32436421 DOI: 10.1177/0300060520926019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
42 Westerling D. Pain management with buprenorphine patches in elderly patients: Quality of life-As good as it gets? Scand J Pain 2015;6:22-3. [PMID: 29911590 DOI: 10.1016/j.sjpain.2014.09.003] [Reference Citation Analysis]
43 Milone MC. Laboratory testing for prescription opioids. J Med Toxicol 2012;8:408-16. [PMID: 23180358 DOI: 10.1007/s13181-012-0274-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
44 Athanasos P, Ling W, Bochner F, White JM, Somogyi AA. Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose. Pain Med 2019;20:119-28. [PMID: 29514333 DOI: 10.1093/pm/pny025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
45 Quirk K, Wright J, Marks A, Smith MA. Sublingual Buprenorphine for Pediatric Cancer Pain: A Case Report and Review of the Literature. Journal of Pain and Symptom Management 2020;60:1055-8. [DOI: 10.1016/j.jpainsymman.2020.07.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Correa-illanes G, Roa RG, B Piñeros JL, Ferrer FT, Adriasola VR. Retrospective analysis of 4 years of clinical experience with transdermal buprenorphine (Transtec ® ) in post-traumatic pain. Pain Management 2014;4:181-90. [DOI: 10.2217/pmt.14.9] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
47 Wallin CM, Bowen SE, Roberge CL, Richardson LM, Brummelte S. Gestational buprenorphine exposure: Effects on pregnancy, development, neonatal opioid withdrawal syndrome, and behavior in a translational rodent model. Drug Alcohol Depend 2019;205:107625. [PMID: 31706250 DOI: 10.1016/j.drugalcdep.2019.107625] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
48 Harrison TK, Kornfeld H, Aggarwal AK, Lembke A. Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy. Anesthesiology Clinics 2018;36:345-59. [DOI: 10.1016/j.anclin.2018.04.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
49 Lazaridou A, Paschali M, Edwards RR, Gilligan C. Is Buprenorphine Effective for Chronic Pain? A Systematic Review and Meta-analysis. Pain Med 2020;21:3691-9. [PMID: 32330264 DOI: 10.1093/pm/pnaa089] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
50 Rosenblum A, Cruciani RA, Strain EC, Cleland CM, Joseph H, Magura S, Marsch LA, McNicholas LF, Savage SR, Sundaram A, Portenoy RK. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol. J Opioid Manag 2012;8:369-82. [PMID: 23264315 DOI: 10.5055/jom.2012.0137] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
51 Whittaker AL, Lymn KA, Wallace GL, Howarth GS. Differential Effectiveness of Clinically-Relevant Analgesics in a Rat Model of Chemotherapy-Induced Mucositis. PLoS One 2016;11:e0158851. [PMID: 27463799 DOI: 10.1371/journal.pone.0158851] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
52 Priestley T, Chappa AK, Mould DR, Upton RN, Shusterman N, Passik S, Tormo VJ, Camper S. Converting from Transdermal to Buccal Formulations of Buprenorphine: A Pharmacokinetic Meta-Model Simulation in Healthy Volunteers. Pain Med 2018;19:1988-96. [PMID: 29036723 DOI: 10.1093/pm/pnx235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
53 Martyn JAJ, Mao J, Bittner EA. Opioid Tolerance in Critical Illness. N Engl J Med 2019;380:365-78. [PMID: 30673555 DOI: 10.1056/NEJMra1800222] [Cited by in Crossref: 62] [Cited by in F6Publishing: 21] [Article Influence: 20.7] [Reference Citation Analysis]
54 Nagar VR, Birthi P, Salles S, Sloan PA. Opioid Use in Chronic Pain Patients with Chronic Kidney Disease: A Systematic Review. Pain Medicine 2017;18:1416-49. [DOI: 10.1093/pm/pnw238] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
55 Drożdżal S, Rosik J, Lechowicz K, Machaj F, Szostak B, Majewski P, Rotter I, Kotfis K. COVID-19: Pain Management in Patients with SARS-CoV-2 Infection-Molecular Mechanisms, Challenges, and Perspectives. Brain Sci 2020;10:E465. [PMID: 32698378 DOI: 10.3390/brainsci10070465] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
56 Infantino R, Mattia C, Locarini P, Pastore AL, Maione S, Luongo L. Buprenorphine: Far Beyond the "Ceiling". Biomolecules 2021;11:816. [PMID: 34072706 DOI: 10.3390/biom11060816] [Reference Citation Analysis]
57 Zimmerman A, Bikdash R, Rauck R. Conversion of Schedule II Opioids to Buprenorphine Buccal Film: A Retrospective Analysis. Pain Med 2021;22:1109-15. [PMID: 32914182 DOI: 10.1093/pm/pnaa226] [Reference Citation Analysis]
58 Attinà G, Romano A, Triarico S, Mastrangelo S, Maurizi P, Ruggiero A. Transdermal buprenorphine for pain management in children. Drugs Context 2021;10:2021-6-1. [PMID: 34567202 DOI: 10.7573/dic.2021-6-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Fishman MA, Scherer A, Topfer J, Kim PSH. Limited Access to On-Label Formulations of Buprenorphine for Chronic Pain as Compared with Conventional Opioids. Pain Med 2020;21:1005-9. [PMID: 31697314 DOI: 10.1093/pm/pnz197] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
60 Zhang Z, Wang X, Li P, Bai M, Qi W. Transdermal delivery of buprenorphine from reduced graphene oxide laden hydrogel to treat osteoarthritis. J Biomater Sci Polym Ed 2021;32:874-85. [PMID: 33570467 DOI: 10.1080/09205063.2021.1877065] [Reference Citation Analysis]
61 Wiegand TJ. The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice. J Med Toxicol 2016;12:64-70. [PMID: 26574020 DOI: 10.1007/s13181-015-0518-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
62 Portenoy RK, Ahmed E. Principles of Opioid Use in Cancer Pain. JCO 2014;32:1662-70. [DOI: 10.1200/jco.2013.52.5188] [Cited by in Crossref: 79] [Cited by in F6Publishing: 18] [Article Influence: 9.9] [Reference Citation Analysis]
63 Kornfeld H, Reetz H. Transdermal Buprenorphine, Opioid Rotation to Sublingual Buprenorphine, and the Avoidance of Precipitated Withdrawal: A Review of the Literature and Demonstration in Three Chronic Pain Patients Treated With Butrans. American Journal of Therapeutics 2015;22:199-205. [DOI: 10.1097/mjt.0b013e31828bfb6e] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 3.4] [Reference Citation Analysis]
64 Kiguchi N, Ding H, Kishioka S, Ko MC. Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics. Curr Top Med Chem 2020;20:2878-88. [PMID: 32384033 DOI: 10.2174/1568026620666200508082615] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
65 Boland JW, Ziegler L, Boland EG, Mcdermid K, Bennett MI. Is regular systemic opioid analgesia associated with shorter survival in adult patients with cancer? A systematic literature review. Pain 2015;156:2152-63. [DOI: 10.1097/j.pain.0000000000000306] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
66 Falcon E, Maier K, Robinson SA, Hill-Smith TE, Lucki I. Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice. Psychopharmacology (Berl) 2015;232:907-15. [PMID: 25178815 DOI: 10.1007/s00213-014-3723-y] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
67 Kosciuczuk U, Knapp P, Lotowska-Cwiklewska AM. Opioid-induced immunosuppression and carcinogenesis promotion theories create the newest trend in acute and chronic pain pharmacotherapy. Clinics (Sao Paulo) 2020;75:e1554. [PMID: 32215455 DOI: 10.6061/clinics/2020/e1554] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
68 Pergolizzi JV, Scholten W, Smith KJ, Leighton-scott J, Willis JC, Henningfield JE. The unique role of transdermal buprenorphine in the global chronic pain epidemic. Acta Anaesthesiologica Taiwanica 2015;53:71-6. [DOI: 10.1016/j.aat.2015.06.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
69 Pergolizzi JV Jr, Magnusson P, LeQuang JA, Breve F, Mitchell K, Chopra M, Varrassi G. Transdermal Buprenorphine for Acute Pain in the Clinical Setting: A Narrative Review. J Pain Res 2021;14:871-9. [PMID: 33833565 DOI: 10.2147/JPR.S280572] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Berna C, Kulich RJ, Rathmell JP. Tapering Long-term Opioid Therapy in Chronic Noncancer Pain. Mayo Clinic Proceedings 2015;90:828-42. [DOI: 10.1016/j.mayocp.2015.04.003] [Cited by in Crossref: 117] [Cited by in F6Publishing: 106] [Article Influence: 16.7] [Reference Citation Analysis]
71 Tang J, Fan J, Yao Y, Cai W, Yin G, Zhou W. Application of a buprenorphine transdermal patch for the perioperative analgesia in patients who underwent simple lumbar discectomy. Medicine (Baltimore) 2017;96:e6844. [PMID: 28514299 DOI: 10.1097/MD.0000000000006844] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
72 Mccormick Z, Chu SK, Chang-chien GC, Joseph P. Acute Pain Control Challenges with Buprenorphine/Naloxone Therapy in a Patient with Compartment Syndrome Secondary to McArdle's Disease: A Case Report and Review. Pain Med 2013;14:1187-91. [DOI: 10.1111/pme.12135] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
73 Desai SN, Badiger SV, Tokur SB, Naik PA. Safety and efficacy of transdermal buprenorphine versus oral tramadol for the treatment of post-operative pain following surgery for fracture neck of femur: A prospective, randomised clinical study. Indian J Anaesth 2017;61:225-9. [PMID: 28405035 DOI: 10.4103/ija.IJA_208_16] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
74 Hale M, Urdaneta V, Kirby MT, Xiang Q, Rauck R. Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids. J Pain Res 2017;10:233-40. [PMID: 28182123 DOI: 10.2147/JPR.S120170] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
75 Miclescu A. The switch from buprenorphine to tapentadol: is it worth? Rom J Anaesth Intensive Care 2016;23:133-9. [PMID: 28913486 DOI: 10.21454/rjaic.7518/232.bup] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Hall OT, Teater J, Rood KM, Phan KL, Clauw DJ. Central sensitization in opioid use disorder: a novel application of the American College of Rheumatology Fibromyalgia Survey Criteria. Pain Rep 2022;7:e1016. [PMID: 35812839 DOI: 10.1097/PR9.0000000000001016] [Reference Citation Analysis]
77 Coluzzi F. Assessing and Treating Chronic Pain in Patients with End-Stage Renal Disease. Drugs 2018;78:1459-79. [PMID: 30206801 DOI: 10.1007/s40265-018-0980-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
78 Rauck RL, Potts J, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain. Postgrad Med 2016;128:1-11. [PMID: 26634956 DOI: 10.1080/00325481.2016.1128307] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
79 Case AA, Kullgren J, Anwar S, Pedraza S, Davis MP. Treating Chronic Pain with Buprenorphine-The Practical Guide. Curr Treat Options Oncol 2021;22:116. [PMID: 34791564 DOI: 10.1007/s11864-021-00910-8] [Reference Citation Analysis]
80 Hale M, Gimbel J, Rauck R. Buprenorphine buccal film for chronic pain management. Pain Management 2020;10:213-23. [DOI: 10.2217/pmt-2020-0013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Kral L, Ku J, Kematick BS, Fudin J. Pearls for opioid use in seriously ill patients. J Pain Palliat Care Pharmacother 2019;33:54-8. [PMID: 31592735 DOI: 10.1080/15360288.2019.1650870] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
82 Gahr M, Eller J, Cabanis M, Hiemke C, Freudenmann RW, Connemann BJ, Lang D, Schönfeldt-lecuona C. Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians. Journal of Substance Abuse Treatment 2017;74:7-15. [DOI: 10.1016/j.jsat.2016.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
83 Gudin J, Fudin J. A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain. Pain Ther 2020;9:41-54. [PMID: 31994020 DOI: 10.1007/s40122-019-00143-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
84 Cisewski DH, Motov SM. Essential pharmacologic options for acute pain management in the emergency setting. Turk J Emerg Med 2019;19:1-11. [PMID: 30793058 DOI: 10.1016/j.tjem.2018.11.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
85 Chen KY, Chen L, Mao J. Buprenorphine-naloxone therapy in pain management. Anesthesiology 2014;120:1262-74. [PMID: 24509068 DOI: 10.1097/ALN.0000000000000170] [Cited by in Crossref: 57] [Cited by in F6Publishing: 19] [Article Influence: 7.1] [Reference Citation Analysis]
86 Calderon R, Copenhaver D. Buprenorphine for chronic pain. J Pain Palliat Care Pharmacother 2013;27:402-5. [PMID: 24245573 DOI: 10.3109/15360288.2013.847522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
87 Schuetze S, Manig A, Ribes S, Nau R. Aged mice show an increased mortality after anesthesia with a standard dose of ketamine/xylazine. Lab Anim Res 2019;35:8. [PMID: 32257896 DOI: 10.1186/s42826-019-0008-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
88 Webster L, Gudin J, Raffa RB, Kuchera J, Rauck R, Fudin J, Adler J, Mallick-Searle T. Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. Pain Med 2020;21:714-23. [PMID: 31917418 DOI: 10.1093/pm/pnz356] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
89 Davis MP, Pasternak G, Behm B. Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option. Drugs 2018;78:1211-28. [PMID: 30051169 DOI: 10.1007/s40265-018-0953-z] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 14.0] [Reference Citation Analysis]
90 Pergolizzi JV Jr, Raffa RB. Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain. J Pain Res 2019;12:3299-317. [PMID: 31997882 DOI: 10.2147/JPR.S231948] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
91 Hale M, Garofoli M, Raffa RB. Benefit-Risk Analysis of Buprenorphine for Pain Management. J Pain Res 2021;14:1359-69. [PMID: 34079354 DOI: 10.2147/JPR.S305146] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Bajic JE, Howarth GS, Mashtoub S, Whittaker AL, Bobrovskaya L, Hutchinson MR. Neuroimmunological complications arising from chemotherapy-induced gut toxicity and opioid exposure in female dark agouti rats. J Neurosci Res 2021. [PMID: 34510524 DOI: 10.1002/jnr.24959] [Reference Citation Analysis]
93 Clark TP, Linton DD, Freise KJ, Reinemeyer C, Newkirk KM, Aulbach A, Lin T. Margin of safety of extended‐duration transdermal buprenorphine solution following multiple‐dose administrations to cats. Vet Pharm & Therapeutics 2022;45. [DOI: 10.1111/jvp.13051] [Reference Citation Analysis]
94 Fishman MA, Kim PS. Buprenorphine for Chronic Pain: a Systemic Review. Curr Pain Headache Rep 2018;22. [DOI: 10.1007/s11916-018-0732-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
95 Bertin C, Delage N, Rolland B, Pennel L, Fatseas M, Trouvin AP, Delorme J, Chenaf C, Authier N. Analgesic opioid use disorders in patients with chronic non-cancer pain: A holistic approach for tailored management. Neurosci Biobehav Rev 2021;121:160-74. [PMID: 33358994 DOI: 10.1016/j.neubiorev.2020.12.015] [Reference Citation Analysis]
96 Fielding F, Sanford TM, Davis MP. Achieving effective control in cancer pain: a review of current guidelines. International Journal of Palliative Nursing 2013;19:584-91. [DOI: 10.12968/ijpn.2013.19.12.584] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
97 Raffa RB, Haidery M, Huang H, Kalladeen K, Lockstein DE, Ono H, Shope MJ, Sowunmi OA, Tran JK, Pergolizzi JV. The clinical analgesic efficacy of buprenorphine. J Clin Pharm Ther 2014;39:577-83. [DOI: 10.1111/jcpt.12196] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 5.5] [Reference Citation Analysis]
98 Shah R, Kuo YF, Baillargeon J, Raji MA. The impact of long-term opioid use on the risk and severity of COVID-19. J Opioid Manag 2020;16:401-4. [PMID: 33428186 DOI: 10.5055/jom.2020.0597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Husmann K, Arlt MJ, Jirkof P, Arras M, Born W, Fuchs B. Primary tumour growth in an orthotopic osteosarcoma mouse model is not influenced by analgesic treatment with buprenorphine and meloxicam. Lab Anim 2015;49:284-93. [PMID: 25650386 DOI: 10.1177/0023677215570989] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
100 Cisewski DH, Santos C, Koyfman A, Long B. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting. Am J Emerg Med 2019;37:143-50. [PMID: 30355476 DOI: 10.1016/j.ajem.2018.10.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
101 Ostrach B, Carpenter D, Cote LP. DEA Disconnect Leads to Buprenorphine Bottlenecks. J Addict Med 2021;15:272-5. [PMID: 33181577 DOI: 10.1097/ADM.0000000000000762] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
102 Browne CA, Lucki I. Targeting opioid dysregulation in depression for the development of novel therapeutics. Pharmacol Ther 2019;201:51-76. [PMID: 31051197 DOI: 10.1016/j.pharmthera.2019.04.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
103 Prommer EE. Pharmacological Management of Cancer-Related Pain. Cancer Control 2015;22:412-25. [DOI: 10.1177/107327481502200407] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]